Form 4: Bio-Techne Corp Executive Matthew McManus Reports Stock Transactions
SEC Form 4 Filing
Matthew McManus, President DGS of Bio-Techne Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.
Summary
- On February 1, 2025, Matthew McManus, President DGS of Bio-Techne Corp, reported transactions involving common stock and derivative securities.
- McManus acquired 4,620 shares of common stock through the vesting of restricted stock units.
- Simultaneously, 1,642 shares were disposed of at a price of $73.55 to satisfy tax obligations.
- Following these transactions, McManus directly owns 2,978 shares of common stock.
- McManus also holds various derivative securities, including performance restricted stock units, stock options, and restricted stock units, with different vesting schedules and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. The vesting of shares is a positive sign, but the disposal to cover taxes is a neutral event.
Positives
- The vesting of restricted stock units indicates that performance milestones were likely achieved, which is a positive signal.
Negatives
- The disposal of shares to cover tax obligations, while common, slightly reduces the executive's direct holdings.
Risks
- Future performance goals tied to the vesting of performance restricted stock units may not be achieved.
- Fluctuations in the stock price could impact the value of the derivative securities held by McManus.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and performance goals associated with these equity grants are typical in the industry.
- The disposal of shares to cover tax obligations is a common practice among executives receiving equity compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- The filing provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | Date of the reported transactions (acquisition and disposal of shares). |
| 02/01/2025 | Vesting date for 4,620 restricted stock units. |
| 02/01/2025 | Vesting date for options to purchase 3,976 shares. |
| 08/15/2025 | Vesting date for 2,637 restricted stock units. |
| 08/15/2025 | Vesting date for options to purchase 5,330 shares. |
| 08/15/2026 | Vesting date for 2,637 restricted stock units. |
| 08/15/2026 | Vesting date for options to purchase 5,330 shares. |
| 02/01/2026 | Vesting date for 4,621 restricted stock units. |
| 02/01/2026 | Vesting date for options to purchase 3,975 shares. |
| 08/15/2026 | Vesting date for performance restricted stock units. |
| 08/15/2027 | Vesting date for 2,638 restricted stock units. |
| 08/15/2027 | Vesting date for options to purchase 5,330 shares. |
| 02/01/2027 | Vesting date for 4,620 restricted stock units. |
| 02/01/2027 | Vesting date for options to purchase 3,976 shares. |
| 08/15/2027 | Vesting date for performance restricted stock units. |
| 02/01/2028 | Vesting date for options to purchase 3,975 shares. |
| 08/15/2028 | Vesting date for options to purchase 5,330 shares. |
| 02/01/2031 | Expiration date for stock options with an exercise price of $68.54. |
| 08/15/2034 | Expiration date for stock options with an exercise price of $74.91. |
Keywords
Form 4, Bio-Techne, McManus, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.